The 36-month beta value for OKYO is also noteworthy at -0.35. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for OKYO is 24.54M, and at present, short sellers hold a 0.73% of that float. The average trading volume of OKYO on April 24, 2025 was 169.48K shares.
OKYO) stock’s latest price update
OKYO Pharma Limited (NASDAQ: OKYO)’s stock price has soared by 11.94 in relation to previous closing price of 1.34. Nevertheless, the company has seen a gain of 33.93% in its stock price over the last five trading days. proactiveinvestors.com reported 2025-04-05 that OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob talked with Proactive about the company’s recent developments, including the formal naming of its drug candidate OK-101 as urcosimod. Jacob discussed the company’s recent Fast Track application to the FDA, aimed at accelerating the regulatory pathway for urcosimod.
OKYO’s Market Performance
OKYO’s stock has risen by 33.93% in the past week, with a monthly rise of 5.63% and a quarterly rise of 44.75%. The volatility ratio for the week is 12.74% while the volatility levels for the last 30 days are 9.76% for OKYO Pharma Limited The simple moving average for the past 20 days is 24.58% for OKYO’s stock, with a 31.49% simple moving average for the past 200 days.
OKYO Trading at 20.66% from the 50-Day Moving Average
After a stumble in the market that brought OKYO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.79% of loss for the given period.
Volatility was left at 9.76%, however, over the last 30 days, the volatility rate increased by 12.74%, as shares surge +7.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +36.36% upper at present.
During the last 5 trading sessions, OKYO rose by +33.93%, which changed the moving average for the period of 200-days by +25.00% in comparison to the 20-day moving average, which settled at $1.2041. In addition, OKYO Pharma Limited saw 30.45% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for OKYO
The total capital return value is set at 0.0.
Based on OKYO Pharma Limited (OKYO), the company’s capital structure generated -0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -0.13.
Currently, EBITDA for the company is 15745.87 with net debt to EBITDA at 295.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.28.
Conclusion
In summary, OKYO Pharma Limited (OKYO) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
